merged_adhd-life-expectancy.txt
<question_number>1</question_number>
<answer>N/A</answer>
<other>The article does not provide enough information to determine the critical methodological difference between the 2022 JAMA Pediatrics meta-analysis and the British study's findings.</other>

<question_number>2</question_number>
<answer>N/A</answer>
<other>The article does not provide information on how Stephen Hinshaw's critique about unrecorded causes of death would invalidate preventive strategies focused solely on the British study's identified comorbidities.</other>

<question_number>3</question_number>
<answer>N/A</answer>
<other>The article does not discuss temporal patterns in A.D.H.D. management adherence or how Russell Barkley's diabetes analogy conflicts with the British study's mortality data.</other>

<question_number>4</question_number>
<answer>N/A</answer>
<other>The article does not provide evidence that undermines the British study's conclusion about A.D.H.D.'s mortality risks when cross-referencing its underdiagnosis caveat with rising adult diagnosis rates in marginalized groups.</other>

<question_number>5</question_number>
<answer>N/A</answer>
<other>The article mentions the Adderall shortage, but it occurred after the British study's observation window (2000-2019), so it does not create a confounding variable for the study's mortality calculations.</other>